Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ARCAGY/ GINECO GROUP
With
AstraZeneca
This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patient older than 18 years.
Patient with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014)
Patient in first line therapy
Available tumor sample fixed in formalin and included in paraffin (FFPE):
* in pre-chemotherapy, insofar as possible
* having a sufficient tumor surface, with a final cellularity of at least 20%
Identification of a molecular genetics' cancer platform participant in GREAT and an onco-geneticists team working with the investigator team
Patient consenting her data to be collected and submitted through an automated processing
Patient beneficiary from the French social security
You may not be if
Patient with a mucinous ovarian carcinoma
Patient pregnant or breastfeeding
Patient under legal protection (guardianship or court order) or unable to consent